Cargando…
Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial
Geraniol is an acyclic monoterpene alcohol with well-known anti-inflammatory and antimicrobial properties which has shown eubiotic activity towards gut microbiota (GM) in patients with irritable bowel syndrome (IBS). Methods: Fifty-six IBS patients diagnosed according to Rome III criteria were enrol...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571173/ https://www.ncbi.nlm.nih.gov/pubmed/36235860 http://dx.doi.org/10.3390/nu14194208 |
_version_ | 1784810296277204992 |
---|---|
author | Ricci, Chiara Rizzello, Fernando Valerii, Maria Chiara Spisni, Enzo Gionchetti, Paolo Turroni, Silvia Candela, Marco D’Amico, Federica Spigarelli, Renato Bellocchio, Irene Marasco, Giovanni Barbara, Giovanni |
author_facet | Ricci, Chiara Rizzello, Fernando Valerii, Maria Chiara Spisni, Enzo Gionchetti, Paolo Turroni, Silvia Candela, Marco D’Amico, Federica Spigarelli, Renato Bellocchio, Irene Marasco, Giovanni Barbara, Giovanni |
author_sort | Ricci, Chiara |
collection | PubMed |
description | Geraniol is an acyclic monoterpene alcohol with well-known anti-inflammatory and antimicrobial properties which has shown eubiotic activity towards gut microbiota (GM) in patients with irritable bowel syndrome (IBS). Methods: Fifty-six IBS patients diagnosed according to Rome III criteria were enrolled in an interventional, prospective, multicentric, randomized, double-blinded, placebo-controlled trial. In the treatment arm, patients received a low-absorbable geraniol food supplement (LAGS) once daily for four weeks. Results: Patients treated with LAGS showed a significant reduction in their IBS symptoms severity score (IBS-SSS) compared to the placebo (195 vs. 265, p = 0.001). The rate of responders according to IBS-SSS (reduction ≥ 50 points) was significantly higher in the geraniol vs placebo group (52.0% vs. 16.7%, p = 0.009) mainly due to the IBS mixed subtype. There were notable differences in the microbiota composition after geraniol administration, particularly a significant decrease in a genus of Ruminococcaceae, Oscillospira (p = 0.01), a decreasing trend for the Erysipelotrichaceae and Clostridiaceae families (p = 0.1), and an increasing trend for other Ruminococcaceae taxa, specifically Faecalibacterium (p = 0.09). The main circulating proinflammatory cytokines showed no differences between placebo and geraniol arms. Conclusion: LAGS was effective in treating overall IBS symptoms, together with an improvement in the gut microbiota profile, especially for the IBS mixed subtype. |
format | Online Article Text |
id | pubmed-9571173 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-95711732022-10-17 Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial Ricci, Chiara Rizzello, Fernando Valerii, Maria Chiara Spisni, Enzo Gionchetti, Paolo Turroni, Silvia Candela, Marco D’Amico, Federica Spigarelli, Renato Bellocchio, Irene Marasco, Giovanni Barbara, Giovanni Nutrients Article Geraniol is an acyclic monoterpene alcohol with well-known anti-inflammatory and antimicrobial properties which has shown eubiotic activity towards gut microbiota (GM) in patients with irritable bowel syndrome (IBS). Methods: Fifty-six IBS patients diagnosed according to Rome III criteria were enrolled in an interventional, prospective, multicentric, randomized, double-blinded, placebo-controlled trial. In the treatment arm, patients received a low-absorbable geraniol food supplement (LAGS) once daily for four weeks. Results: Patients treated with LAGS showed a significant reduction in their IBS symptoms severity score (IBS-SSS) compared to the placebo (195 vs. 265, p = 0.001). The rate of responders according to IBS-SSS (reduction ≥ 50 points) was significantly higher in the geraniol vs placebo group (52.0% vs. 16.7%, p = 0.009) mainly due to the IBS mixed subtype. There were notable differences in the microbiota composition after geraniol administration, particularly a significant decrease in a genus of Ruminococcaceae, Oscillospira (p = 0.01), a decreasing trend for the Erysipelotrichaceae and Clostridiaceae families (p = 0.1), and an increasing trend for other Ruminococcaceae taxa, specifically Faecalibacterium (p = 0.09). The main circulating proinflammatory cytokines showed no differences between placebo and geraniol arms. Conclusion: LAGS was effective in treating overall IBS symptoms, together with an improvement in the gut microbiota profile, especially for the IBS mixed subtype. MDPI 2022-10-10 /pmc/articles/PMC9571173/ /pubmed/36235860 http://dx.doi.org/10.3390/nu14194208 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ricci, Chiara Rizzello, Fernando Valerii, Maria Chiara Spisni, Enzo Gionchetti, Paolo Turroni, Silvia Candela, Marco D’Amico, Federica Spigarelli, Renato Bellocchio, Irene Marasco, Giovanni Barbara, Giovanni Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial |
title | Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial |
title_full | Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial |
title_fullStr | Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial |
title_full_unstemmed | Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial |
title_short | Geraniol Treatment for Irritable Bowel Syndrome: A Double-Blind Randomized Clinical Trial |
title_sort | geraniol treatment for irritable bowel syndrome: a double-blind randomized clinical trial |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9571173/ https://www.ncbi.nlm.nih.gov/pubmed/36235860 http://dx.doi.org/10.3390/nu14194208 |
work_keys_str_mv | AT riccichiara geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT rizzellofernando geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT valeriimariachiara geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT spisnienzo geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT gionchettipaolo geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT turronisilvia geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT candelamarco geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT damicofederica geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT spigarellirenato geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT bellocchioirene geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT marascogiovanni geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial AT barbaragiovanni geranioltreatmentforirritablebowelsyndromeadoubleblindrandomizedclinicaltrial |